Amphastar Pharmaceuticals Inc
NASDAQ:AMPH

Watchlist Manager
Amphastar Pharmaceuticals Inc Logo
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Watchlist
Price: 45.46 USD 2.04% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Amphastar Pharmaceuticals Inc?
Write Note

Amphastar Pharmaceuticals Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amphastar Pharmaceuticals Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Selling, General & Administrative
-$92.9m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
Johnson & Johnson
NYSE:JNJ
Selling, General & Administrative
-$22.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
0%
Bristol-Myers Squibb Co
NYSE:BMY
Selling, General & Administrative
-$8B
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
-5%
Pfizer Inc
NYSE:PFE
Selling, General & Administrative
-$14.8B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
0%
Merck & Co Inc
NYSE:MRK
Selling, General & Administrative
-$10.7B
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Selling, General & Administrative
-$8.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-2%
No Stocks Found

Amphastar Pharmaceuticals Inc
Glance View

Market Cap
2.2B USD
Industry
Pharmaceuticals

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. The firm is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. Its segments include Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes Primatene Mist, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Glucagon for injection emergency kit is indicated for the treatment of severe hypoglycemia.

AMPH Intrinsic Value
62.15 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Amphastar Pharmaceuticals Inc's Selling, General & Administrative?
Selling, General & Administrative
-92.9m USD

Based on the financial report for Sep 30, 2024, Amphastar Pharmaceuticals Inc's Selling, General & Administrative amounts to -92.9m USD.

What is Amphastar Pharmaceuticals Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-9%

Over the last year, the Selling, General & Administrative growth was -24%. The average annual Selling, General & Administrative growth rates for Amphastar Pharmaceuticals Inc have been -10% over the past three years , -7% over the past five years , and -9% over the past ten years .

Back to Top